Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Decibel Therapeutics

decibeltx.com

Latest From Decibel Therapeutics

Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate

The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.

Deals Business Strategies

Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C

Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.

Financing StartUps and SMEs

Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m

Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.

Financing StartUps and SMEs

Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine

Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Otolaryngology
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Decibel Therapeutics
  • Senior Management
  • Steven Holtzman, Pres. & CEO
    Michael SU, PhD, CSO
    John J Lee, SVP, Pharmaceutical Dev.
    Paula K Cobb, COO
    Ronald Vigliotta, Sr. Dir., Finance
    Peter Weber, MD, CMO
  • Contact Info
  • Decibel Therapeutics
    Phone: (617) 370-8701
    1325 Boylston Street
    Ste. 500
    Boston, MA 02215
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register